Percutaneous device closure of patent foramen ovale for secondary stroke prevention: A call for completion of randomized clinical trials: A science advisory from the American heart association/American stroke association and the American college of cardiology foundation

Circulation

Volumn 119, Issue 20, 2009, Pages 2743-2747

  O'Gara, Patrick T ^a   Messe, Steven R ^a   Tuzcu, E Murat ^a   Catha, Gloria ^a   Ring, John C ^a  

^a NONE

Author keywords

AHA Scientific Statements; Aneurysm; Anticoagulation; Antiplatelet agents; Patent foramen ovale; Stroke; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; WARFARIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OBSERVATIONAL STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PATENT FORAMEN OVALE; PERCUTANEOUS DEVICE CLOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SURGICAL EQUIPMENT; SURGICAL TECHNIQUE; SUTURE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

AMERICAN HEART ASSOCIATION; CARDIAC SURGICAL PROCEDURES; EQUIPMENT AND SUPPLIES; FORAMEN OVALE, PATENT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL; STROKE; UNITED STATES;

EID: 67249104994     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.192272     Document Type: Article

References (38)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statis-tics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-e146.
2. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ische-mic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in Circulation. 2006;114:e617]. Circulation. 2006;113: e873-e923.
3. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention. Circulation. 2006;113:e409-e49.
4. Sacco RL, Elllenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-90.
5. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST, Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24:35-41.
6. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001; 32:2559-66.
7. Lee BC, Hwang SH, Jung S, et al. The Hallym Stroke Registry: a web-based stroke data bank with an analysis of 1,654 consecutive patients with acute stroke. Eur Neurol. 2005;54:81-8.
8. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
9. Di Tullio MR, Sacco RL, Sciacca RR, et al. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol. 2007;49:797-802.
10. Meissner I, Khandheria BK, Heit JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47:440-5.
11. Attaran RR, Ata I, Kudithipudi V, et al. Protocol for optimal detection and exclusion of a patent foramen ovale using transthoracic echocardi-ography with agitated saline microbubbles. Echocardiography. 2006;23: 616-22.
12. Miigge A, Daniel WG, Angermann C, et al. Atrial septal aneurysm in adult patients: a multicenter study using transthoracic and transesopha-geal echocardiography. Circulation. 1995;91:2785-92.
13. Srivastava TN, Payment MF. Images in clinical medicine: paradoxical embolism-thrombus in transit through a patent foramen ovale. N Engl J Med. 1997;337:681.
14. Lethen H, Flachskampf FA, Schneider R, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol. 1997;80:1066-9.
15. Stollberger C, Slany J, Schuster I, et al. The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism [published correction appears in Ann Intern Med. 1994;120:347]. Ann Intern Med. 1993;119:461-5.
16. Homma S, Sacco RL. Contemporary reviews in cardiovascular medicine: patent foramen ovale and stroke. Circulation. 2005;112:1063-72.
17. Halperin JL, Fuster V. Patent foramen ovale and recurrent stroke: another paradoxical twist. Circulation. 2002;105:2580-2.
18. Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Stroke. 2002;33:706-11.
19. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale In Cryptogenic Stroke Study. Circulation. 2002;105:2625-31.
20. Handke M, Harloff A, Olschewski M, et al. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262-8.
21. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-6.
22. Wohrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet. 2006;368:350-2.
23. Homma S, DiTullio MR, Sacco RL, et al. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke. 2004;35:2145-9.
24. Bogousslavsky J, Garazi S, Jeanrenaud X, et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study: Lausanne Stroke with Paradoxal Embolism Study Group. Neurology. 1996;46:1301-5.
25. Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol. 1999;15:57-64.
26. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139:753-60.
27. Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(suppl):593S-629S.
28. Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyond equipoise. JAMA. 2005;294:366-9.
29. Flachskampf FA, Daniel WG. Closure of patent foramen ovale: is the case really closed as well? Heart. 2005;91:449-50.
30. Dalen JE. Are patients with a patent foramen ovale at increased risk of stroke? A billion dollar question. Am J Med. 2007;120:472-4.
31. Opotowsky AR, Landzberg MJ, Kimmel SE, Webb GD. Trends in the use of percutaneous closure of patent foramen oval and atrial septal defect in adults, 1998-2004. JAMA. 2008;299:521-2.
32. Information for Physicians and Patients on the Withdrawal of Two Humanitarian Device Exemptions (HDEs) for Patent Foramen Ovale (PFO) Occluders. US Food and Drug Administration Web site. 2006. Available at: http://www.fda.gov/cdrh/ode/h000007-h990011withdraw.html. Accessed January 14, 2008. ing=PFO. Accessed January 6, 2009.
33. RESPECT: Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment Web page. Available at: http://www.strokecenter.org/trials/trialDetail.aspx?tid=482&search
34. CLOSURE 1: Evaluation of the STARFlex Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO). Available at: http://www.clinicaltrials. gov/ct2/show/NCT00201461?term=PFO+AND+stroke&rank=5. Accessed March 20, 2009.
35. GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients (Gore REDUCE). Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00738894?term=NCT00738894&rank=l. Accessed March 20, 2009.
36. Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (CLOSE). Available at: http://www. clinicaltrials.gov/ct2/show/NCT00562289?term=PFO+AND+stroke&rank=4. Accessed January 6, 2009.
37. PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00166257?term=PFO+AND+stroke&rank= 8. Accessed March 20, 2009.
38. Slottow TL, Steinberg DH, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation. 2007;116:677-82.